Allergy Immunotherapy (Desensitization)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage, and investigational exclusions for allergy immunotherapy (subcutaneous and select rapid/desensitization procedures) for Blue Cross Blue Shield of North Carolina members and describes coding/billing and guideline expectations for providers.
No material clinical or coverage changes in this revision.
Coverage criteria and exclusions
When Allergy Immunotherapy is covered
Covered when ALL of the following are met
From policy: candidates must have demonstrated hypersensitivity (see testing).
Policy indicates immunotherapy is for individuals whose symptoms are not controlled by medications and avoidance measures.
Policy specifies injections of airborne or insect venom allergens should be prepared individually.
Rush immunotherapy indications (nested OR logic)
- ONE of: a) Allergy to a particular drug that cannot be treated effectively with alternative medications (drug desensitization covered only when no alternative and for life‑threatening condition);
From policy: drug desensitization considered medically necessary only when no alternative drug is available.
- ONE of: b) Insect sting (Hymenoptera) hypersensitivity (eg, wasps, hornets, bees, fire ants);
Policy lists insect sting hypersensitivity as an indication for rush protocols.
- ONE of: c) Moderate to severe allergic rhinitis requiring treatment during or immediately before the allergy season affecting the patient;
Policy added this indication for rush immunotherapy in 2015.
Policy requires adherence to specialty practice parameters and appropriately trained providers.
Rush immunotherapy safety and administration criteria
Requirements and safety considerations for rush protocols
Describes the nature and increased risk of rush schedules; from policy guidelines.
Policy states premedication primarily with antihistamines and corticosteroids appears to reduce risk.
Policy cites studies and practice parameters recommending longer observation after rush protocols.
Reflects Joint Task Force practice parameter language cited in policy.
Coverage stance and administrative limits
Policy-level coverage and investigational statements (historical and update notes).
Covers investigational stance and the COVID‑19 exception history as recorded in implementation notes.
From the Billing/Coding section and implementation updates indicating per‑unit reimbursement and rolling calendar year accumulation.
Subcutaneous immunotherapy administered in the home setting is considered investigational and is not covered.
A limited temporary exception for home-administered subcutaneous immunotherapy was implemented during the COVID-19 pandemic (variously effective from March 6, 2020 through dates in 2021). That exception was later removed and the policy was revised to state that subcutaneous immunotherapy performed in the home setting is considered investigational.
Allergy immunotherapy is considered investigational and not covered for several indications, including chronic urticaria; angioedema; food allergy; migraine headaches; non-allergic vasomotor rhinitis; and intrinsic (non-allergic) asthma. The policy also lists multiple investigational treatments and techniques (for example, provocative/neutralization therapy for food allergies by any route, most forms of sublingual immunotherapy except specified FDA-approved products, urine autoinjections, repository emulsion therapy, low-dose 'Rinkel' technique, enzyme‑potentiated desensitization, acupuncture/homeopathy for allergies, rhinophototherapy, and oral mucosal immunotherapy such as Allerdent® compounded toothpaste) as not covered.
Reiterating policy stance: home-administered subcutaneous immunotherapy is treated as investigational/not covered under the standard policy. Although a COVID-19 era exception was applied for limited dates in 2020–2021, that exception was removed and the investigational designation reinstated.
Applicable service codes, unit limits, and coding history
| 30999 | Unlisted procedure, nervous system (listed in policy as applicable service code) |
| 86003 | Allergen specific IgE; quantitative or semi-quantitative, each |
| 86005 | Allergen specific IgE; qualitative or semiquantitative, multiple |
| 95115 | Professional services for allergen immunotherapy not otherwise specified |
| 95117 | Allergen immunotherapy, single injection |
| 95120 | Allergen immunotherapy, each additional injection |
| 95125 | Allergen immunotherapy, single physician-provided extract |
| 95130 | Allergen immunotherapy, venom (Hymenoptera), single injection |
| 95131 | Allergen immunotherapy, venom, each additional injection |
| 95132 | Allergen immunotherapy, venom, multivalent |
| 0168T | Deleted code (reference to prior deletion from billing/coding section) |
| 30999 | Added to Billing/Coding section (unspecified use in these chunks) |
| Oralair | FDA-approved sublingual immunotherapy product (listed by name) |
| Grastek | FDA-approved sublingual immunotherapy product (listed by name) |
| Ragwitek | FDA-approved sublingual immunotherapy product (listed by name) |
| Odactra | FDA-approved product noted in When Not Covered section update |
Provider obligations, documentation, and billing rules
Coverage based on medical necessity; codes and reimbursement limits apply
Coverage for allergy immunotherapy is determined by medical necessity per the policy; applicable service codes are listed in the Billing/Coding section and per-unit reimbursement limits apply (see Billing/Coding for unit limits).
- Applicable service codes are listed in the Billing/Coding section (e.g., 30999, 86003, 95115, 95117, 95120, 95125, 95130, 95131, 95132, 95133, 95134, 95144, 95145, 95146, 95147, 95148, 95149, 95165, 95170, 95180, 95199, J7999).
- Per-unit reimbursement limits apply (see Billing/Coding: unit limits for first year escalation and yearly maintenance).
Billing basis and accumulation rules
Per-unit reimbursement is based on the number of dosages prepared and intended for administration; accumulation of service for billing is counted on a rolling calendar year.
- Reimbursement basis: number of dosages prepared and intended for administration.
- Accumulation: rolling calendar year.
Provider actions — apply medical necessity and coding guidance
When providing allergy immunotherapy services, follow the policy’s medical necessity criteria and billing guidance; ensure documentation supports coverage decisions and coding aligns with the listed applicable service codes.
- Confirm that clinical indications meet the policy’s 'When Allergy Immunotherapy is covered' criteria before billing.
- Use the applicable service codes listed in the Billing/Coding section when submitting claims.
Step therapy requirements
No step therapy requirements are specified in the policy chunks provided.
- The policy indicates: 'No step therapy requirements specified in these chunks.'
Include full clinical details when records are requested
If medical records are requested to determine medical necessity, include all specific clinical details required by the policy; letters of support alone are insufficient unless they contain all required information.
- Include clinical evidence of demonstrated hypersensitivity (testing results) and documentation that symptoms are not controlled by medications or avoidance.
- When submitting letters of support, ensure they contain the full details needed to make a medical necessity determination.
Verify benefits and eligibility before applying policy
Verify member benefits and eligibility per the group contract and subscriber certificate before applying the medical policy guidelines.
- Benefits and eligibility are determined before medical guidelines and payment guidelines are applied and are governed by the group contract and subscriber certificate in effect at the time services are rendered.
Provide requested medical records or risk denial
BCBSNC may request medical records to determine medical necessity; failure to provide required documentation can result in denial.
- Letters of support and/or explanation are not sufficient unless they include all specific information needed to make a medical necessity determination.
- Ensure complete clinical records are available if requested to avoid denial.
Home subcutaneous immunotherapy may be denied (investigational)
Subcutaneous immunotherapy performed in the home setting is considered investigational and may be denied; a limited COVID-19-era exception applied for defined periods but was later removed.
- Policy states: 'Subcutaneous immunotherapy performed in the home setting is considered investigational.'
- A temporary COVID-19 exception (effective March 6, 2020 through various extension dates) was implemented and later removed; standard policy treats home administration as investigational.
Key definitions
Background and clinical context
Allergy immunotherapy (subcutaneous injections) is intended to reduce patient sensitivity to identified allergens by administering incremental doses beginning at low levels with gradual escalation to a maintenance dose. It is indicated when allergens have been identified by appropriate skin or in vitro testing and symptoms are not adequately controlled by medications or avoidance. Build-up continues until maintenance intervals (typically every 2–6 weeks) are achieved, and therapy may continue for several years. Rush (rapid desensitization) protocols accelerate attainment of the maintenance dose over 1–3 days but carry a higher risk of systemic reactions and therefore require appropriate premedication, extended observation, and administration by trained personnel in a setting equipped to recognize and treat anaphylaxis.
Policy revision history
Guidelines section reformatted; statements deleted from 'When Allergy Immunotherapy is covered' (Specialty Matched Consultant Panel review 7/14/08); references updated.
Added statement that home subcutaneous immunotherapy is investigational and defined per-unit reimbursement limits of 180 units first year and 120 units maintenance; FDA-approved sublingual products (Oralair, Grastek, Ragwitek) referenced.
'When Covered' updated to include an additional indication for rush immunotherapy for moderate to severe allergic rhinitis requiring treatment during or immediately before the allergy season.
Related Policies section updated (Specialty Matched Consultant Advisory Panel review 11/2019).
Home subcutaneous immunotherapy was made investigational except under medical or nursing supervision during the COVID-19 pandemic (effective March 6, 2020).
COVID-19 exception for supervised home subcutaneous immunotherapy extended through June 30, 2021 with periodic reevaluation.
Clarified that accumulation of service for allergy immunotherapy billing is based on a rolling calendar year.
COVID-19 exception removed and home subcutaneous immunotherapy reinstated as investigational (standard policy position).
Added reimbursement policy 'Maximum Units of Service' to Related Policies.
References updated and 'When Covered' edited for clarity with no change to policy statement (Specialty Matched Consultant Advisory Panel review 11/2023).
References updated (Specialty Matched Consultant Advisory Panel review 11/2024).
References updated (Specialty Matched Consultant Advisory Panel review 11/2025; Medical Director review 11/2025).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.